Search the Newsreel

Earnings Flash (PBEE.L) PensionBee Group Reports H1 Revenue GBP26.4M

Insight Enterprises (NSIT) Shares Jumped, So What Is Behind The Move?

Insight Enterprises (NSIT) saw its shares jump after strong Q2 2026 results, driven by demand for AI infrastructure and cloud services, leading to raised full-year guidance. While analysts widely consider the stock overvalued at $107.50 compared to its current price of $154.74, Simply Wall …

NSI N.V.: Herziening en evolutie van de omzet- en toekomstige winsttaxaties | N4RN | NL0012365084

NSI N.V.: Financiële gegevens voorspellingen Ramingen en verwachtingen | N4RN

Intensity Therapeutics (Nasdaq:INTS) - Stock Analysis

Intensity Therapeutics (Nasdaq:INTS) is a late-stage clinical biotechnology company focused on developing INT230-6 for cancer treatment. The company recently provided updates on its INVINCIBLE-4 study for triple-negative breast cancer and the INVINCIBLE-3 study for soft tissue sarcoma, with preliminary positive results and plans for …

NSI N.V.: beurskoers Aandeel | N4RN | NL0012365084

NSI N.V.: Fundamentele analyse en financiële beoordelingen | N4RN | NL0012365084

Advait Energy Transitions Limited (ADVAIT.NS) stock price, news, quote and history

Ensign Investor News: If You Have Suffered Losses in The

The Rosen Law Firm is investigating potential securities claims against The Ensign Group, Inc. (NASDAQ: ENSG) following allegations of misleading business information. This investigation stems from a short seller report claiming Ensign's business model relies on inadequate patient care and understaffing, leading to an …

Ensign Group (ENSG) Stock Drops 8% After Hunterbrook Media Report as Law Firm Launches Securities Investigation

The Ensign Group (ENSG) saw its stock drop 8% after a Hunterbrook Media report alleged patient care deficiencies and manipulation of quality data in its nursing home operations. Following this, the law firm Kaplan Fox & Kilsheimer LLP launched an investigation into ENSG for …

China Sunsine Chemical's Attributable Profit Up 5% in H1

The Ensign Group, Inc. $ENSG is Wasatch Advisors LP's 2nd Largest Position

Wasatch Advisors LP has significantly increased its stake in The Ensign Group, Inc. (NASDAQ:ENSG), making it their second-largest holding, owning 3.90% of the company worth $365.2 million. Other institutional investors have also adjusted their positions in ENSG. The article also details recent insider stock …

Nano Dimension (NNDM) Projected to Release Earnings on Wednesday

Assenagon Asset Management S.A. Has $7.40 Million Holdings in Insight Enterprises, Inc. $NSIT

Assenagon Asset Management S.A. significantly increased its stake in Insight Enterprises, Inc. (NASDAQ:NSIT) by 34.6% in the second quarter, bringing its total holdings to $7.40 million. This move is part of a broader trend of institutional investors expanding their positions in Insight Enterprises, reflecting …

Sensient Technologies (NYSE:SXT) Hits New 12-Month High - What's Next?

Sensient Technologies (NYSE:SXT) recently hit a new 52-week high of $132.47, driven by favorable analyst ratings and strong quarterly earnings. The company exceeded expectations with $1.20 EPS and $462.08 million in revenue, leading analysts like UBS and Robert W. Baird to raise their price …

Insight Enterprises’s Q2 Earnings Call: Our Top 5 Analyst Questions

Insight Enterprises's Q2 Earnings Call: Our Top 5 Analyst Questions Insight Enterprises delivered results for Q2 that surpassed Wall Street's expectations, with management highlighting robust demand for infrastructure hardware and continued momentum in cloud and core services. CEO Jack Azagury cited over 20% growth …

Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment

Intensity Therapeutics reported a net loss of $3.0 million for Q2 2026 and held $9.5 million in cash. The company resumed limited clinical activities for its INVINCIBLE-3 and INVINCIBLE-4 trials, with preliminary INVINCIBLE-4 data showing promising results in pathological complete response and reduced adverse …

Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket

Intensity Therapeutics (INTS) reported a wider-than-expected Q2 2026 loss of $1.11 per share, missing analyst estimates by $0.24, causing its shares to fall 4.62% premarket. The clinical-stage biotech is advancing its INVINCIBLE-3 and INVINCIBLE-4 cancer trials, having secured over $23 million in funding over …

Insight Digital Partners II (DYOR) Earnings Date and Reports 2026

Insight Digital Partners II (DYOR) reported its Q2 2026 earnings on August 11, 2026, with an EPS of $0.06. The company's stock closed at $10.10 on August 11, 2026. Investors can sign up for alerts to stay updated on future earnings announcements and reports.

Truist Financial Maintains AdvanSix(ASIX.US) With Hold Rating, Announces Target Price $18

Truist Financial has reiterated its Hold rating for AdvanSix (ASIX.US) and set a target price of $18. This indicates their neutral outlook on the company's stock performance.

Insight Molecular Diagnostics to Host Virtual KOL Event on

Insight Molecular Diagnostics Inc. (iMDx) will host a virtual KOL event on August 17, 2026, to discuss its GraftAssure platform and the potential for in-house heart transplant rejection testing. The event will feature Dr. Max Jacob Liebo, alongside iMDx's VP of Medical Affairs and …

Doctors to discuss in-house heart transplant testing Aug. 17

Insight Molecular Diagnostics (Nasdaq: IMDX) will host a virtual Key Opinion Leader (KOL) event on August 17, 2026, to discuss its GraftAssure dd-cfDNA platform. The event will feature cardiologist Max Jacob Liebo, MD, and iMDx executives, focusing on the GraftAssureDx kit for kidney and …

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

Earnings Call Insights: Intensity Therapeutics (INTS) Q2 2026 MANAGEMENT VIEW * "It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studies, our business development activities, and our plans for the second half of 2026" (Founder, …

Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com

This article reports that Intensity Therapeutics Inc. filed a Form 8K on August 11, 2026. The Form 8K is a crucial document used by public companies to notify investors of significant events that shareholders should know about. No specific details about the content of …

Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY

Insight Digital Partners II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary

INTENSITY THERAPEUTICS, INC. reported a net loss of $(3.0M) for Q2 2026, an increase from $(2.5M) in Q2 2025, with a diluted loss per share of $(1.11). The company remains pre-revenue but has made progress in its clinical programs, including initiating Phase 3 and …

Sensient Technologies Corporati (SXT) Stock Forecasts

Argus has raised its target price for Sensient Technologies Corp (SXT) to $134.00, citing the company's role as a manufacturer and marketer of natural and synthetic colors, flavors, and other specialty ingredients. The current price of SXT stock is $130.33. This report provides a …

Insight Digital Partners (DYOR) earns $2.7M but flags going concern risk

Insight Digital Partners II Q2 2026: Net income $1.4M, EPS $0.06— 10-Q Summary

Insight Digital Partners II reported net income of $1.4 million for Q2 2026, with diluted earnings per share of $0.06. For the first six months of 2026, consolidated net income was $2.66 million and diluted EPS was $0.12. The company's business focus is on …

InSilico Medicine Sets Board Meeting to Approve Interim Results and Dividend

Advait Energy Transitions wins Rs 24.88 crore order from Getco

Nsing Technologies Schedules Board Meeting to Approve 2026 Interim Results

The Ensign Group, Inc. (ENSG) Stock Analysis: Navigating a 20% Potential Upside Amid Strong Revenue Growth

The Ensign Group, Inc. (ENSG) presents a compelling investment opportunity with a potential upside of 20% due to strong revenue growth and positive analyst sentiment. Despite its stock being in overbought territory, the company demonstrates efficient management, profitability, and strategic expansion within the healthcare …

California State Teachers Retirement System Grows Holdings in Insight Enterprises, Inc. $NSIT

The California State Teachers Retirement System significantly increased its stake in Insight Enterprises (

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …